-
In the evening after work, and in a generally relaxed environment, subjects had their coronary flow velocities in the left anterior descending artery recorded by non-invasive transthoracic Doppler echocardiography, and coronary flow velocity reserve (CFVR) was calculated. CFVR was assessed at baseline and immediately following 30 minutes of lavender aromatherapy, as were serum cortisol levels.
-
Irritable Bowel Syndrome (IBS) is a chronic gastrointestinal (GI) illness that is defined by symptoms of bloating, lower abdominal pain, and abnormal defecation patterns after evaluation excludes colitis or structural abnormalities as the cause.
-
The second part of this series reviews specific features of dietary intake that can influence fertility as well as overall general medical health.
-
Reflexology is an ancient therapy that has become popular in some health care settings. Its use with cancer patients arises from its reputation for reducing pain, relieving anxiety, and promoting relaxation.
-
-
The dramatic reduction in in-stent restenosis (ISR) afforded by drug-eluting stents (DES) led to their widespread use throughout the world. Subsequently, more patients and lesions could be treated percutaneously with less thought about ISR. With the advent of a more widespread adoption of percutaneous coronary intervention, registry data began suggesting an increased risk of late and very late stent thrombosis with DES compared to bare-metal stents (BMS).
-
The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)-Prevenzione trial demonstrated a lower mortality rate in post myocardial infarction patients treated with n-3 polyunsaturated fatty acids (PUFA) vs controls, which was mainly due to a reduction in sudden death.
-
In this paper, Adabag et al from the Mayo Clinic analyzed the risk of sudden death after an acute myocardial infarction over a 28-year period in patients residing in Olmsted County, MN.
-
-
Prasugrel, a novel third-generation oral thienopyridine (following ticlopidine and clopidogrel), has recently been shown to provide clinically important platelet inhibition in acute coronary syndromes (ACS), with decreased ischemic events compared to clopidogrel in the TRITON-TIMI 38 trial of almost 14,000 ACS patients undergoing PCI.
